A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2002 participants.
Also called NCT03730662
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,002 participants
- Sponsor
- Registry
-
NCT03730662 -
2018-002618-11
-
- Other papers using this trial's data
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Canada, Greece, Israel, Mexico, Poland, Puerto Rico, Romania, Russia, Slovakia, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT03730662. Randomized; no masking; primary purpose treatment. Start 2018-11-20 (actual); primary completion 2021-01-22 (actual). Results posted on 2022-02-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
- Acronym
- SURPASS-4
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03730662- Content hash
15b87af8fe3d30cab4a71084121eefc2647ff2e236e2e3eefed2cc80e86a2ceb